WHO WE ARE
We Are All In
Guided by science, we are relentlessly committed to bringing transformative new medicines to patients with oncogene amplified cancer. Requisite to our success are boldness, creativity, and collaboration.
United in purpose, we are a team of experienced precision oncology leaders with deep scientific, clinical, diagnostic, and business expertise. We are applying this experience to develop an entirely new wave of therapeutics, ecDNA-directed therapies (“ecDTx”).
At Boundless, we’re all in. We are unbound by convention, bound to save lives.
Board Of Directors
Stephen Benkovic, Ph.D.
Evan Pugh University Professor and Eberly Chair in Chemistry at The Pennsylvania State University
Howard Chang, M.D., Ph.D.
Virginia and D.K. Ludwig Professor of Cancer Genomics and Genetics at Stanford University
Paul Mischel, M.D.
Institute Scholar, ChEM-H; Vice Chair of Research and Professor, Dept of Pathology, Stanford University Chairman of the Scientific Advisory Board